Zosano Pharma Corp Income Statement

Ask AI

Financial Statements

In millions of USD; shares in millions, except per-share amounts

	FY2021 12 months to Dec 31, 2021	FY2020 12 months to Dec 31, 2020	FY2019 12 months to Dec 31, 2019	FY2018 12 months to Dec 31, 2018	FY2017 12 months to Dec 31, 2017
Revenue
Service revenue
Operating expenses:
Cost of service revenue
Research and development
General and administrative
Impairment loss
Total operating expenses
Loss from operations
Other income (expense):
Interest expense, net
Interest income
Interest expense
Other income (expense), net

Loss before provision for income taxes
Provision for income taxes
Net loss
Unrealized gain on marketable securities, net of tax
Comprehensive loss
Net loss per common share – basic and diluted (in USD per share)
Weighted-average common shares used in computing net loss per common share – basic and diluted (in shares)
Net loss per common share – basic (in USD per share)
Net loss per common share – diluted (in USD per share)
Weighted-average common shares used in computing net loss per common share – basic (in shares)
Weighted-average common shares used in computing net loss per common share – diluted (in shares)

Comments